Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Celcuity Inc. (CELC)

125.65 +4.30 (+3.54%)
At close: May 1 at 4:00:00 PM EDT
143.00 +17.35 (+13.81%)
After hours: May 1 at 7:59:54 PM EDT
Trade CELC on Coinbase
Chart Range Bar
Loading chart for CELC
  • Previous Close 121.35
  • Open 121.02
  • Bid 90.69 x 100
  • Ask 156.46 x 100
  • Day's Range 117.50 - 127.89
  • 52 Week Range 9.51 - 129.09
  • Volume 1,813,212
  • Avg. Volume 748,731
  • Market Cap (intraday) 6.074B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) --
  • EPS (TTM) -3.79
  • Earnings Date (est.) May 13, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 130.55

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

www.celcuity.com

155

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: CELC

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CELC
25.98%
S&P 500 (^GSPC)
5.62%

1-Year Return

CELC
1,063.43%
S&P 500 (^GSPC)
29.01%

3-Year Return

CELC
1,195.36%
S&P 500 (^GSPC)
73.47%

5-Year Return

CELC
354.27%
S&P 500 (^GSPC)
72.92%

Earnings Trends: CELC

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -38.45M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-30M
-20M
-10M
0

Analyst Insights: CELC

View More

Analyst Price Targets

94.00 Low
130.55 Average
125.65 Current
155.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/27/2026
Analyst Citizens
Rating Action Initiated
Rating Market Outperform
Price Action Announces
Price Target 150

Statistics: CELC

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    6.07B

  • Enterprise Value

    5.95B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    60.40

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.24%

  • Return on Equity (ttm)

    -163.80%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -177.04M

  • Diluted EPS (ttm)

    -3.79

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    441.5M

  • Total Debt/Equity (mrq)

    320.13%

  • Levered Free Cash Flow (ttm)

    -96.05M

Compare To: CELC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CELC

Fair Value

125.65 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: